1. Introduction {#s0005}
===============

Pregnancy failure and placenta mediated pregnancy complications (PMPC), miscarriage, fetal growth restriction (FGR), pre-eclampsia (PE) and abruption, collectively affect over 25% of pregnancies. Fifteen per cent of clinically recognized pregnancies end in miscarriage, with 5% of women experiencing ≥ 2 losses, and 1--2% ≥ 3 losses ([@bb0120]). With assisted conception, 76.3% of all cycles (that include such PMPC) do not result in a live birth ([@bb0090]). Diagnosis of PMPC is largely based on clinical outcome rather than cause, despite heterogeneous disease processes generating the same clinical pregnancy outcome ([@bb0070]). The largest single cause of first trimester miscarriage is due to embryo aneuploidy. The remainder are unexplained, reflecting limited knowledge of implantation and placentation. The current focus on precision medicine ([@bb0035]) emphasizes the need to stratify PMPC by mechanism, without which potential therapies may be rejected as ineffective when assessed in a heterogeneous patient group ([@bb0070]). For PMPC there is biological plausibility for coagulation activation being an underlying mechanism in a proportion of these events. The pathological features include deficient implantation, placental infarction, and microvascular thrombosis ([@bb0070]). The biological plausibility is enhanced by our knowledge of antiphospholipid syndrome, which is associated with thrombotic placental damage, and increased thrombin generation. Antithrombotic therapy guided by a biomarker, antiphospholipid antibodies, is associated with improved pregnancy outcome ([@bb0070], [@bb0045]). In contrast, trials of antithrombotic intervention in unselected women at risk of PMPC, based on outcome of previous pregnancies, has been found to be ineffective ([@bb0070], [@bb0080], [@bb0030], [@bb0100], [@bb0115], [@bb0135]). However, an approach based on stratification for a specific thrombotic process underlying these PMPC, would be appropriate before discarding such treatment. This requires a biomarker. One possible biomarker is Annexin--A5 (ANXA5), an anticoagulant protein highly expressed on the apical surfaces of syncytiotrophoblasts, ANXA5 prevents coagulation processes by forming a two dimensional lattice which can be disrupted by antiphospholipid antibodies ([@bb0160]), and has been reported to promote cell membrane repair in the syncytiotrophoblast layer ([@bb0015]). The annexin A5 M2 haplotype (ANXA5 M2) is associated with reduced expression of ANXA5 in placentas from M2 haplotype carriers presenting with PE and FGR ([@bb0110], [@bb0020], [@bb0095]). Further, the M2 haplotype is associated with an increased risk of PMPCs: recurrent pregnancy loss (RPL) ([@bb0010], [@bb0140], [@bb0105], [@bb0130], [@bb0150], [@bb0075], [@bb0040]), FGR ([@bb0140]) small for gestational age infants ([@bb0145]), and gestational hypertension ([@bb0140]). The haplotype is transmitted equally by males and females ([@bb0110], [@bb0020], [@bb0095], [@bb0130]).

In a single study using a murine knockout model, significant reductions both in litter size and fetal weight in ANXA5-null mice (ANXA5-KO) was reported ([@bb0155]), if accepted this suggests that maternal expression of ANXA5 in the circulation may be crucial for maintaining normal pregnancy; further administration of heparin on pregnancy days 12, 14, 16 and 18 to ANXA5-KO mice significantly increased litter size so contributing to the biological plausibility for the use for heparin for an intervention.

This study investigated, for the first time, the pragmatic use of the maternal and paternal ANXA5 M2 haplotype as a biomarker to stratify couples at risk of pregnancy failure undergoing assisted conception, for antithrombotic intervention with low molecular weight heparin (LMWH).

2. Methods {#s0010}
==========

2.1. Study Population {#s0015}
---------------------

Three patient cohorts and a retrospective contemporaneous group of unscreened patients undergoing assisted conception treatment, at five fertility clinics within in the CARE Fertility Group (CFG) were studied as follows.•To evaluate the association of the ANXA5 haplotype in a retrospectively tested group of 171 females with adverse outcome and 154 of their partners whose sperm were used. Seventy-seven of these couples had one or both partners who were ANXA5 M2 positive. These formed the "Yardstick" reference cohort (N = 77)•A Randomly selected unscreened retrospective contemporaneous patient couple group (N = 1000)•A Prospective, Tested and Treated couple cohort not taken from the retrospective contemporaneous group (N = 103)•A matched retrospective control couple cohort (N = 103) selected from the 1000 retrospective contemporaneous group

Patients were followed until either clinical miscarriage or in live birth or other pregnancy outcome.

2.2. Yardstick Reference Group {#s0020}
------------------------------

This "Yardstick" reference group permitted observation of the timing of pregnancy losses in untreated M2 carrier couples. ANXA5 M2 screening was performed in 171 female patients and their partners (17 using sperm donors were not tested), with at least one failed previous IVF cycle (mean 1.10). None had achieved a live birth previously, 26% had a previous miscarriage, and their mean duration of infertility was 4.17 years. There were 77 couples (45%) where one or both partners were carriers of ANXA5 M2 (two females were egg recipients and three couples had sperm donation, the donors were not screened). This group had a similar age to the tested and treated cohort (median 35 range 25--44). The timing of losses in this group were compared to those of the unscreened, untreated, retrospective contemporaneous group.

2.3. Retrospective Unscreened Untreated Contemporaneous Group {#s0025}
-------------------------------------------------------------

Of the 1000 couples, 110 were egg recipients, 38 were egg share donors. The patients\' ages, infertility status and ethnicity were as described by [@bb0055].

2.4. Tested and Treated Cohort {#s0030}
------------------------------

696 patients (369 couples) elected prospectively to be screened for carriage of the ANXA5 M2 haplotype. The first 103 patient couples found to be ANXA5 M2 positive were enlisted to the cohort and treated with a prophylactic dose of LMWH on achieving embryo transfer following informed consent, between March 2012 and October 2014. Patient enlistment was based on their own and their clinician\'s decision to test and treat considering their clinical history, which included duration of infertility, numbers of previous failed cycles and miscarriages. This was conducted as a clinical practice study with patient information documents to guide informed consent. Independent counselling was offered to all patients.

2.5. Matched Controls {#s0035}
---------------------

The Tested and Treated cohort was matched with a cohort of 103 retrospective untested and untreated controls drawn from the randomly selected group of 1000 unscreened patient couples achieving embryo transfer with no LMWH treatment. The matching characteristics are shown in [Table 1](#t0005){ref-type="table"}. None of the treated or control patients had achieved a live birth previously.

Reporting of this study conforms to the STROBE (The Strengthening the Reporting of Observational Studies in Epidemiology) statement.

2.6. Ethical Statement and Informed Consent {#s0040}
-------------------------------------------

Clinic practice and procedures are regulated and routinely inspected by the Human Fertilisation and Embryology Authority (HFEA), thus the Internal Review Board (IRB)/external ethical committee are used for clinical trials and embryo research only. This was a clinical observational study for a test and treatment regime for recurrent pregnancy loss that had limited published evidence and as such all CARE medical directors agreed, following their individual clinical judgement to offer the test to patients who had full counselling, written detailed information and signed informed consent based upon patient clinical history. These forms are available for scrutiny.

2.7. Study Design {#s0045}
-----------------

The study was a pragmatic prospective cohort study of LWMH treatment in IVF couples offered screening and found positive for the ANXA5 M2 haplotype, compared to retrospective matched unscreened and untreated, couples (controls). No exclusions were made. The patient characteristics are shown in [Table 1](#t0005){ref-type="table"}. Ovulation induction and embryology protocols and procedures have been published previously ([@bb0050]). In the tested and treated group, if either or both of the couple were carriers of the M2 haplotype, the female received LMWH (enoxaparin: Clexane; Sanofi Winthrop, France) subcutaneously in a dose of 40 mg daily beginning on the day of oocyte retrieval for fresh embryo transfer or, on the day of frozen embryo transfer, and for a minimum of 12 weeks, with the recommendation to continue until term.

Women were assessed for TH1/TH2 intracellular cytokine ratio, Natural Killer cells and HLADQ at the discretion of the treating clinician. Where the TH1/TH2 intracellular cytokine ratio was disturbed (n = 50), Intralipid® 20% (Fresenius Kabi, New Zealand) was administered ([@bb0085]).

2.8. Outcome Measures {#s0050}
---------------------

The primary outcome measure was the incidence of live birth. Secondary outcomes were: incidence of implantation, biochemical pregnancy loss rate, clinical pregnancy rate, clinical miscarriage rate, live birth rate outcome by gender and M2 carriage, and allelic dose influence. Preclinical miscarriage was defined as failure of pregnancy after a positive biochemical pregnancy test and no fetal heart at first ultrasound examination at 5--6 weeks from day of embryo transfer; and clinical miscarriage was defined as pregnancy loss after detection of fetal heart activity.

2.9. Genotyping and Quality Control {#s0055}
-----------------------------------

DNA collection and analysis together with genotyping was performed, by Sanger sequencing as previously described ([@bb0055]). Purified amplicons were sequenced using standard conditions and electrophoresis on an ABI 3730xl DNA analyser.

2.10. Statistical Analysis {#s0060}
--------------------------

Statistical analysis was independently conducted by Qi Statistics Ltd., Reading, UK. The analyses included: Mantel-Haenzel chi-squared tests for trend to assess the statistical significance of the association between i) treatment group and ii) each pregnancy outcome and each of the ordinal baseline characteristics. Pearson chi-squared tests for general association were used to assess the statistical significance of the association between treatment cohort and of each of the binary and nominal baseline characteristics, and Fisher\'s Exact Test was used where the expected counts were very low. All tests were 2-sided and statistical significance was viewed as accepted if the p-value was \< 0.05.

2.11. Statistical Software {#s0065}
--------------------------

All analyses were performed in the statistical software package SAS v9.3 (SAS Institute Inc., 2002--2010). The SAS procedure 'PROC FREQ' (Base SAS 9.3 Procedures Guide: Statistical Procedures) was used to perform all tests of association ([@bb0005]). Paired Controls were randomly selected from each matched subgroup by generating random numbers using the CALL RANUNI subroutine with SAS.

2.12. Independent Variables {#s0070}
---------------------------

In addition to the study cohort (treatment/control), data on the following independent variables were evaluated: patient age (years), ANXA5 M2 genotyping results (female and male), number of embryos transferred, stage of embryo development at transfer (1--8 cells morula, blastocyst), type of incubator (EmbryoscopeTM/standard), duration of infertility (years), number of previous IVF cycles, number of previous miscarriages, use of intralipid, donor egg use (egg recipient or egg share donor).

All data was obtained from the Clinical Information system (CIS) After 12 weeks clinical miscarriages live births and all other pregnancy outcomes were reported by the patient in compliance with the Human Fertility and Embryo Authority (HFEA) requirements.

2.13. Paired Analyses {#s0075}
---------------------

The matched cohort of 103 paired Controls was drawn from the 1000 retrospective unscreened, untreated contemporaneous couple group by finding the number of Tested and Treated and Control patients that fell into each of the cross-classifications of baseline characteristics namely; age, number of embryos transferred, type of embryo transferred, previous failed miscarriages, previous failed IVF cycles and egg recipients (a total of 144 possible groups). As this was a pragmatic study of screening and treatment versus non screening, it is important to note that a proportion of the controls will be undetected ANXA5 M2 positive. It has previously been estimated that 44% of couples would be expected to be M2 positive in this IVF population ([@bb0055]). Thus 1000 patient couples could be expected to include 440 M2 carrier couples (one or both partners\' carriers).

3. Results {#s0080}
==========

The yardstick reference group M2 positive couples had poor pregnancy outcome with high rates of pregnancy loss at various stages and no live births. [Table 2](#t0010){ref-type="table"} shows where in gestation each pregnancy was lost at each stage up to and including clinical miscarriage, so enabling comparisons of the timing of pregnancy loss for the Yardstick and the retrospective, unscreened, untreated contemporaneous 1000 couple group.

Excluding egg recipients, the untreated ANXA5 M2 carrier Yardstick group had a statistically higher incidence of implantation, biochemical and clinical pregnancy than Controls. Their clinical miscarriages all occurred by 12 weeks gestation: two at 6 weeks one at 7 weeks, four at 8 weeks, four at 9 weeks and two at 12 weeks gestation. The incidence of implantation and clinical pregnancy was significantly higher than either controls or egg recipients, but patients then lost their clinical pregnancies. Thus the untreated M2 carriers have a different pattern of timing of loss both to the unscreened, untreated standard controls and to unscreened, untreated egg recipients.

The Tested and Treated cohort, with a potential for more adverse outcome due to a higher mean maternal age, a greater number of miscarriages, a longer duration of infertility, and more unsuccessful assisted conception cycles, achieved a live birth rate of 37.9%, compared to the 1000 retrospective unscreened and untreated group of 38.5% ([Table 3](#t0015){ref-type="table"}). Statistical analysis showed no significant impact of the use of Embryoscope™ time-lapse incubators and Intralipid (data not shown but provided in Supplementary Tables). Significantly more favorable outcomes were observed for younger patients, egg recipients and for those who had blastocysts or two earlier cleavage stage embryos transferred (data not shown but provided in Supplementary Tables).

The Tested and Treated cohort had a similar outcome to the Paired Control cohort See [Table 4](#t0020){ref-type="table"}.

Of the four clinical miscarriages in the Tested and Treatment cohort, one was due to chorionamnionitis at 15 weeks gestation; one was a twin pregnancy with Dandy Walker variant delivered at 23 weeks, and two at 12--13 weeks with no diagnosis made.

The seven clinical miscarriages in the matched control cohort occurred at 8, 9, 10, 11, 12, 13 (twins) and 19 weeks respectively with no diagnosis made. Three of these controls were egg recipients.

Comparing couples with only males who demonstrated carrier or homozygosity, to couples where only the female had carrier/homozygous status, the live birth outcome is statistically significantly different at the 5% level (p = 0.0452) with 58.3% of male ANXA5 M2 only treated couples having a live birth versus 25.0% of female ANXA5 M2 only treated couples ([Table 5](#t0025){ref-type="table"}). This result is close to the statistically significant cut-off so needs to be interpreted in the context of the size of the difference and the population.

There is no statistically significant evidence of an allelic dose effect on live birth outcome.

4. Discussion {#s0085}
=============

The Yardstick reference group allowed observation of the gestational stage at which pregnancy losses occur following ET, and demonstrate the known association ([@bb0110], [@bb0095], [@bb0140], [@bb0130]) between ANXA5 M2 parental status and adverse outcome, with higher risk of early clinical pregnancy loss.

The timing of clinical pregnancy loss is consistent with the previously reported time of loss in natural pregnancies with ANXA5 M2 carriers with RPL ([@bb0010], [@bb0140], [@bb0105], [@bb0150], [@bb0075], [@bb0040]).

The association between parental M2 status and adverse clinical pregnancy outcomes, coupled with the biological plausibility of the M2 haplotype operating through procoagulant mechanisms leads to the hypothesis that the M2 haplotype acts as a biomarker for adverse pregnancy outcome, which is amenable to intervention with LMWH.

Stratification of assisted conception patients by parental ANXA5 M2 status would offer targeted intervention with LMWH, delivering a precision medicine approach.

The lack of such stratification may underlie the inconsistent data from trials of LMWH for PMPC ([@bb0100], [@bb0125]) due to inclusion of heterogeneous disease mechanisms rather than a focus on those associated with a procoagulant mechanism. These findings also suggest that for LMWH treatment to be effective it should be introduced before a clinical pregnancy is confirmed, as later initiation appears too late to improve live birth. The timing of LMWH administration may also have been a factor in the outcome of trials of LMWH for recurrent pregnancy loss, where treatment was often started following diagnosis of clinical pregnancy and LMWH was without benefit ([@bb0080], [@bb0030], [@bb0115], [@bb0135]). The ANXA5 M2 haplotype may also be a relevant biomarker to stratify treatment in a proportion of unexplained infertility and recurrent miscarriage cases and should be explored.

This concept of the parental M2 Haplotype, acting as a biomarker to stratify assisted conception patients for LMWH therapy, was explored in the cohort comparison described in this paper. The results of the cohort comparison show that a tested and treated cohort of ANXA5 M2 carriers do not achieve a significantly different live birth rate (37.9%) per embryo transfer cycle both in comparison to a larger, unselected, untreated, more fertile group and to a paired cohort who would both have a lower prevalence of M2. Additionally the live birth rate of 37.9% compares favorably to the live birth rate per embryo cycle of 36.1% achieved from 6572 fresh embryo transfer cycles in CARE patients using their own eggs in the two years 2013 and 2014. It is further of note that whereas in 2014 the HFEA reported that the mean age of women having IVF treatment was 35 and their duration of infertility (DOI) was 4 years,67% of the tested and treated cohort in this study were aged 35 and over (median age 38) and had an mean DOI of 5.1 years These data suggest that screening for ANXA5 M2 haplotype and treatment with LMWH can improve prognosis for M2 positive couples, to that expected in a first assisted conception cycle in the general population.

The ANXA5 M2 haplotype has been reported to pose an equal risk whether transmitted paternally or maternally ([@bb0110], [@bb0020], [@bb0095], [@bb0130], [@bb0040]). However, the significant difference in live birth outcome reported in [Table 5](#t0025){ref-type="table"} between treated male only carrier couples versus treated female only carrier couples (p = 0.045) suggests an additional maternal thrombophilic factor that may further adversely affect pregnancy outcome. Ota et al. ([@bb0110]) noted that women with recurrent pregnancy loss suffer repeat miscarriages even though the maternal and paternal ANXA5 M2 haplotype will be transmitted to the fetus/placenta with a 50% frequency. The possibility that the ANXA5 M2 haplotype is a thrombophilia is also supported by [@bb0060], [@bb0065] who reported that deep vein thrombosis in men and nonpregnant women ([@bb0060]), and in pregnant women ([@bb0065]) is independently associated with M2 status. The less favorable outcome for female only carriers or homozygotes versus males also suggests that the maternal contribution is not confined to the transmission of the M2 haplotype to the fetus and needs further elucidation. There is growing evidence that male factors are important for abnormal placentation and the development of PE ([@bb0165]). The association shown in this study of the paternal ANXA5 M2 haplotype with adverse outcomes adds weight to the hypothesis that male factors play also play a role in PMPC.

In the cohorts studied, duration of infertility, type of incubator and the use of intralipid did not have any bearing on pregnancy outcome. The effect of allelic dose (1 versus 2 or 3 alleles) as reported by [@bb0040] is not observed in this study.

This may be because the allelic dose effect has been reduced by LMWH treatment.

4.1. Limitations of the Study {#s0090}
-----------------------------

Classically for a confirmatory trial it is required to specify upfront the clinically meaningful difference of interest and then set up the trial to adequately collect the right amount of data, However, conducting randomized controlled trials in the assisted conception population is inherently difficult as advancing maternal age is associated with a decline in fertility and such females are reluctant to be randomized. Trials of this type in naturally-conceived pregnancy require several years to complete, for example the TIPPS trial of antithrombotic intervention for women with thrombophilia in pregnancy ([@bb0125]) took 12 years. There is further difficulty in spontaneous pregnancy if LMWH is to be introduced early in pregnancy. Given the effect of age on fertility, the age of the patient cohort, the impact of age on treatment outcome, and the time required to perform a randomized trial in this population, a pragmatic approach to screening and treatment was preferred with rigorous matching of variables. [@bb0025] has suggested that cohort-controlled are useful in identifying variables associated with treatment outcomes before proceeding to an RCT. Therefore a pragmatic approach as described here with a retrospective case control design is the most practicable first step in assessing the hypothesis that the ANXA5 M2 haplotype is a biomarker for IVF failure, which can be overcome by treatment with LMWH.

Based on the work of [@bb0055] the highest incidence we may estimate for control IVF couples positive for M2 would be 44%; hence the M2 dilution effect would be at the least a factor of 2.3 (100/44).

Within the known limitations of the study and the population, however, no significant evidence was found for differences between the groups in terms of the primary live birth outcome.

4.2. Conclusions {#s0095}
----------------

In conclusion, this study suggests that the identification and treatment of M2 carrier pregnancies by screening both partners for the M2 haplotype, in assisted reproduction, may identify an adverse prognostic factor for assisted conception, which can be used to stratify couples for treatment with LMWH. Such an intervention results in live birth outcomes similar to those achieved in assisted conception cohorts with more favorable prognostic factors. This study also suggests that such treatment should be started prior to clinical pregnancy. In view of its association with PMPC particularly in the first trimester of pregnancy, studies on the role of the M2 haplotype are warranted in these conditions.
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###### 

Matching variables for Treated and Paired Control patient cohorts.

Table 1

                                                           Tested and Treated   Matched controls              
  ------------------------------- ------------------------ -------------------- ------------------ ---------- ----------
  Egg recipients                  Egg recipient            8                    7.8%               8          7.8%
  Standard                        95                       92.2%                95                 92.2%      
  Number of embryos transferred   1                        38                   36.9%              38         36.9%
  2                               64                       62.1%                64                 62.1%      
  3                               1                        1.0%                 1                  1.0%       
  Embryo type                     Cells 1 to 8 +           45                   43.7%              45         43.7%
  Morula                          3                        2.9%                 3                  2.9%       
  Blastocysts/compacting          55                       53.4%                55                 53.4%      
  No aged \</≥ 35 years           \< 35                    34                   33.0%              34         33.0%
  ≥ 35                            69                       67.0%                69                 67.0%      
  Age of patient (years)          \< 35: median; (range)   32                   (26--34)           32         (22--34)
  ≥ 35: median; (range)           38                       (35--47)             38                 (35--45)   
  Median; (range)                 36                       (26--47)             36                 (22--45)   
  Previous failed IVF cycles      0                        17                   16.5%              26         25.2%
  1 +                             86                       83.5%                77                 74.8%      
  Previous miscarriages           0                        53                   51.5%              56         54.4%
  1 +                             50                       48.5%                47                 45.6%      

###### 

Pregnancy failures showing where losses occur in untreated groups after embryo transfer.

Table 2

                                                                    Unscreened untreated group   Unscreened untreated group   Yardsticks   p-Value
  ----------------------------------------------------------------- ---------------------------- ---------------------------- ------------ -----------
  Number of patients with failed live birth after embryo transfer   75                           534                          75           
  Number of embryos transferred                                     106                          774                          115          
  Number of embryos with fetal heart activity detected              9                            31                           12           
  Implantation incidence (fetal hearts/embryos transferred)         8.5%                         4.0%                         10.4%        0.0027
  Positive pregnancy test                                           30                           88                           28           
  Biochemical pregnancy rate (per patient)                          40.0%                        16.5%                        37.3%        \< 0.0001
  Biochemical loss/preclinical miscarriage                          23                           58                           16           
  Biochemical loss rate                                             76.7%                        65.9%                        57.1%        0.4005
  Clinical pregnancy                                                7                            30                           12           
  Clinical pregnancy rate                                           9.3%                         5.6%                         16.0%        0.0009
  Clinical miscarriage                                              5                            30                           12           
  Clinical miscarriage rate                                         85.7%                        100.0%                       100.0%       

Note: one control egg recipient and one egg donor were lost to follow up after clinical pregnancy and outcome unknown so assumed to have maintained pregnancy.

Note that only patients with an embryo transfer that failed to result in a live birth have been included.

9 control patients with an ectopic pregnancy or termination were excluded.

###### 

Pregnancy outcome for patients with an embryo transfer.

Table 3

                                                                                                                                         Study group      Odds ratio (95% CI) (Treated cohort/Unscreened untreated)   p-Value (Treated vs. Unscreened untreated)   
  -------------------------------------------------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------------- -------------------------------------------- ------
  Patients with an embryo transfer                                                                                                       103              1000                                                                                                     
  Number of embryos transferred                                                                                                          169              1454                                                                                                     
  Number of embryos transferred with fetal heart activity subsequently detected                                                          56               494                                                                                                      
  Implantation incidence (fetal hearts/embryos transferred)                                                                              33.1%            34.0%                                                       0.96 (0.69, 1.35)                            0.83
  Biochemical pregnancy rate (per patient)                                                                                               53.4% (N = 55)   50.9% (N = 509)                                             1.11 (0.74, 1.66)                            0.63
  Biochemical loss rate (per biochemical pregnancy)                                                                                      21.8% (N = 12)   15.9% (N = 81)                                              1.47 (0.75, 2.92)                            0.26
  Clinical pregnancy rate (per patient)                                                                                                  41.7% (N = 43)   42.8% (N = 428)                                             0.96 (0.63, 1.44)                            0.84
  Patients with clinical miscarriages (miscarriages after fetal hearts detected)                                                         4                36                                                                                                       
  Patients with ectopic or terminated clinical pregnancy                                                                                 0                9                                                                                                        
  Clinical miscarriage rate (per clinical pregnancy)[a](#tf0005){ref-type="table-fn"}                                                    9.3%             8.6%                                                        1.09 (0.37, 3.23)                            0.87
  Patients with live births                                                                                                              39               373                                                                                                      
  Patients lost to follow up/live birth data unavailable                                                                                 0                9                                                                                                        
  Live birth rate (per patient)[a](#tf0005){ref-type="table-fn"}, [b](#tf0010){ref-type="table-fn"}, [c](#tf0015){ref-type="table-fn"}   37.9%            38.5%                                                       0.97 (0.64, 1.48)                            0.89

Excludes eight controls with a termination of pregnancy after patients electing to have amniocentesis or chorionvillous biopsy and one control with an ectopic pregnancy.

Note that for the purposes of calculating the Live Birth Rate per patient, nine Control patients with Clinical Pregnancy who were lost to follow up were assumed to have had a live birth.

Includes one live birth (499 g) to a Control patient that was neonatal death.

###### 

Pregnancy outcome for matched Treated and Paired Control cohorts.

Table 4

  Pregnancy outcomes                                                                        Study group      Odds ratio (95% CI) (Treated/Control)   p-Value (Treated vs. Control)   
  ----------------------------------------------------------------------------------------- ---------------- --------------------------------------- ------------------------------- ------
  Paired patients with an embryo transfer                                                   103              103                                                                     
  Number of embryos transferred                                                             169              169                                                                     
  Number of embryos transferred with fetal hearts detected                                  56               51                                                                      
  Implantation incidence (fetal hearts/embryos transferred)                                 33.1%            30.2%                                   1.15 (0.72, 1.81)               0.56
  Biochemical pregnancy rate (per patient)                                                  53.4% (N = 55)   46.6% (N = 48)                          1.31 (0.76, 2.27)               0.33
  Biochemical loss rate (per biochemical pregnancy)                                         21.8% (N = 12)   14.6% (N = 7)                           1.63 (0.59, 4.56)               0.35
  Clinical pregnancy rate (per patient)                                                     41.7% (N = 43)   39.8% (N = 41)                          1.08 (0.62, 1.89)               0.78
  Clinical miscarriage rate (per clinical pregnancy)                                        9.3% (N = 4)     17.1% (N = 7)                           0.49 (0.13, 1.85)               0.29
  Patients with live births                                                                 39               34                                                                      
  Patients lost to follow up/live birth data unavailable[a](#tf0020){ref-type="table-fn"}   0                1                                                                       
  Live birth rate (per patient)                                                             37.9%            33.0%                                   1.24 (0.70, 2.19)               0.47

1 patient was lost to follow up in the control cohort after clinical pregnancy at 12 weeks and has been included as a live birth.

###### 

Live births for treated patients by carrier status and allelic dose.

Table 5

  All treated patients with complete genetic testing data                                                                                               
  --------------------------------------------------------- --------------------------- ------- ------- ------- ------- ------------------------------- --------
  C4M2 carrier status                                       Female carrier/homozygote   9       25.0%   26      43.3%   35                              
  Male carrier/homozygote                                   21                          58.3%   23      38.3%   44      0.0452 (Male vs. Female only)   
  Both carrier/homozygote                                   6                           16.7%   11      18.3%   17                                      
  Number of alleles                                         1                           29      39.7%   44      60.3%   73                              0.4222
  2 to 3                                                    7                           30.4%   16      69.6%   23                                      

1 includes: (WT/WT)/(WT/M2); (WT/WT)/(M1/M2); (WT/M2)/(WT/M1); (WT/M2)/(M1/M1).

2 includes: (WT/M2)/(WT/M2); (WT/M2)/(M1/M2); (WT/WT)/(M2/M2); (WT/M1)/(M2/M2).

3 includes: (WT/M2)/(M2/M2).

Seven couples with incomplete genetic testing data have been excluded (five untested males and two untested females).
